17728

533138

ASTEC

img img img img
No Data Available

ASTEC LIFESCIENCES LTD Share Price Update

As of the latest trading session, ASTEC LIFESCIENCES LTD is trading at ₹771.8, up by ₹35.14 or 4.77% from its previous close. The stock has moved between ₹723.90 and ₹788.15 today. Over the past year, the stock has delivered a return of 10.62%. In the last month, it has returned 4.21%.

ASTEC LIFESCIENCES LTD performance

Today’s low Today’s high
₹ 723.90 ₹ 788.15
₹ 771.80
52 week low 52 week high
₹ 513.40 ₹ 990.82
₹ 771.80
Open Price ₹ 742.30
Prev. Close ₹ 736.65
Volume (Shares) 120066.00
Total traded value ₹ 926.66
Upper Circuit ₹ 883.95
Lower Circuit ₹ 589.35
info

Investment Returns

Over 1 Month 4.21% Over 3 Months 23.40% Over 6 Months -13.28% Over 1 Year 10.62%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

ASTEC LIFESCIENCES LTD fundamentals


  • Market cap (Cr) 1,719.70
  • P/E Ratio (TTM) -21.25
  • Beta 1.13
  • Book Value / share 174.96
  • Return on equity -44.73%
  • EPS (TTM) 0.00
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) -7.78
info icon alternate text
  • Market cap (Cr) 1,721.60
  • P/E Ratio (TTM) -21.25
  • Beta 1.07
  • Book Value / share 174.96
  • Return on equity -44.73%
  • EPS (TTM) 0.00
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) -7.78
info icon alternate text

ASTEC LIFESCIENCES LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 158.62
Operating Expense 169.18
Net Profit -7.78
Net Profit Margin (%) -4.90
Earnings Per Share (EPS) -3.49
EBITDA 11.77
Effective Tax Rate (%) 2.01
Particulars DEC 2025 (Values in Cr)
Revenue 124.72
Operating Expense 139.14
Net Profit -15.72
Net Profit Margin (%) -12.60
Earnings Per Share (EPS) -7.06
EBITDA 2.69
Effective Tax Rate (%) 0.00
Particulars SEP 2025 (Values in Cr)
Revenue 73.72
Operating Expense 99.27
Net Profit -24.45
Net Profit Margin (%) -33.16
Earnings Per Share (EPS) -11.39
EBITDA -5.57
Effective Tax Rate (%) 0.00
Particulars JUN 2025 (Values in Cr)
Revenue 91.08
Operating Expense 124.63
Net Profit -33.06
Net Profit Margin (%) -36.29
Earnings Per Share (EPS) -16.86
EBITDA -10.50
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 119.53
Operating Expense 135.99
Net Profit -16.10
Net Profit Margin (%) -13.46
Earnings Per Share (EPS) -8.21
EBITDA 6.30
Effective Tax Rate (%) -2.61
Particulars MAR 2026 (Values in Cr)
Revenue 448.15
Operating Expense 532.21
Net Profit -81.01
Net Profit Margin (%) -18.07
Earnings Per Share (EPS) -37.83
EBITDA -1.60
Effective Tax Rate (%) 0.19
Particulars MAR 2025 (Values in Cr)
Revenue 381.30
Operating Expense 527.98
Net Profit -134.81
Net Profit Margin (%) -35.35
Earnings Per Share (EPS) -68.74
EBITDA -60.63
Effective Tax Rate (%) 4.47
Particulars MAR 2024 (Values in Cr)
Revenue 458.18
Operating Expense 525.64
Net Profit -46.99
Net Profit Margin (%) -10.25
Earnings Per Share (EPS) -23.96
EBITDA -0.32
Effective Tax Rate (%) 24.06
Particulars MAR 2023 (Values in Cr)
Revenue 628.17
Operating Expense 606.35
Net Profit 25.52
Net Profit Margin (%) 4.06
Earnings Per Share (EPS) 13.02
EBITDA 89.30
Effective Tax Rate (%) 26.77
Particulars MAR 2022 (Values in Cr)
Revenue 676.57
Operating Expense 565.99
Net Profit 89.82
Net Profit Margin (%) 13.27
Earnings Per Share (EPS) 45.85
EBITDA 164.55
Effective Tax Rate (%) 25.79
Particulars MAR 2025 (Values in Cr)
Book Value / Share 119.70
ROE % -44.60
ROCE % -12.60
Total Debt to Total Equity 1.74
EBITDA Margin -15.89
Particulars MAR 2024 (Values in Cr)
Book Value / Share 188.32
ROE % -11.89
ROCE % -4.49
Total Debt to Total Equity 1.06
EBITDA Margin -0.06
Particulars MAR 2023 (Values in Cr)
Book Value / Share 213.90
ROE % 6.27
ROCE % 7.73
Total Debt to Total Equity 0.76
EBITDA Margin 14.22
Particulars MAR 2022 (Values in Cr)
Book Value / Share 202.32
ROE % 25.47
ROCE % 22.17
Total Debt to Total Equity 0.66
EBITDA Margin 24.32
Particulars MAR 2021 (Values in Cr)
Book Value / Share 157.84
ROE % 23.42
ROCE % 22.27
Total Debt to Total Equity 0.51
EBITDA Margin 21.53
Particulars MAR 2025 (Values in Cr)
Book Value / Share 119.36
ROE % -44.73
ROCE % -12.62
Total Debt to Total Equity 1.74
EBITDA Margin -15.90
Particulars MAR 2024 (Values in Cr)
Book Value / Share 188.01
ROE % -11.93
ROCE % -4.50
Total Debt to Total Equity 1.06
EBITDA Margin -0.07
Particulars MAR 2023 (Values in Cr)
Book Value / Share 213.61
ROE % 6.26
ROCE % 7.73
Total Debt to Total Equity 0.76
EBITDA Margin 14.22
Particulars MAR 2022 (Values in Cr)
Book Value / Share 202.06
ROE % 25.49
ROCE % 22.17
Total Debt to Total Equity 0.66
EBITDA Margin 24.32
Particulars MAR 2021 (Values in Cr)
Book Value / Share 157.60
ROE % 23.31
ROCE % 22.18
Total Debt to Total Equity 0.52
EBITDA Margin 21.48
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.70
Total Assets 881.42
Total Liabilities 881.42
Total Equity 235.01
Share Outstanding 1
Price to Book Ratio 5.65
Return on Assets (%) -15.28
Return on Capital (%) -17.07
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 2.43
Total Assets 974.92
Total Liabilities 974.92
Total Equity 369.51
Share Outstanding 1
Price to Book Ratio 5.65
Return on Assets (%) -4.81
Return on Capital (%) -5.44
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 2.15
Total Assets 979.41
Total Liabilities 979.41
Total Equity 419.55
Share Outstanding 1
Price to Book Ratio 6.47
Return on Assets (%) 2.61
Return on Capital (%) 3.36
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.12
Total Assets 896.75
Total Liabilities 896.75
Total Equity 396.65
Share Outstanding 1
Price to Book Ratio 8.67
Return on Assets (%) 10.02
Return on Capital (%) 13.29
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.57
Total Assets 677.58
Total Liabilities 677.58
Total Equity 309.31
Share Outstanding 1
Price to Book Ratio 6.35
Return on Assets (%) 9.60
Return on Capital (%) 13.1
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1.49
Total Assets 880.41
Total Liabilities 880.41
Total Equity 234.07
Share Outstanding 1
Price to Book Ratio 5.65
Return on Assets (%) -15.31
Return on Capital (%) -17.09
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.39
Total Assets 974.14
Total Liabilities 974.14
Total Equity 368.67
Share Outstanding 1
Price to Book Ratio 5.65
Return on Assets (%) -4.82
Return on Capital (%) -5.45
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1.37
Total Assets 978.84
Total Liabilities 978.84
Total Equity 418.79
Share Outstanding 1
Price to Book Ratio 6.47
Return on Assets (%) 2.60
Return on Capital (%) 3.36
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.81
Total Assets 896.70
Total Liabilities 896.70
Total Equity 395.98
Share Outstanding 1
Price to Book Ratio 8.67
Return on Assets (%) 10.01
Return on Capital (%) 13.3
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.56
Total Assets 677.89
Total Liabilities 677.89
Total Equity 308.70
Share Outstanding 1
Price to Book Ratio 6.35
Return on Assets (%) 9.54
Return on Capital (%) 13.05
Particulars MAR 2025 (Values in Cr)
Net Income -140.98
Cash from Operations -13.39
Cash from Investing -15.23
Cash from Financing 23.73
Net change in Cash 0.10
Free Cash Flow 8.43
Particulars MAR 2024 (Values in Cr)
Net Income -61.74
Cash from Operations 12.18
Cash from Investing -135.18
Cash from Financing 124.95
Net change in Cash 0.00
Free Cash Flow 147.68
Particulars MAR 2023 (Values in Cr)
Net Income 34.94
Cash from Operations 79.54
Cash from Investing -112.50
Cash from Financing 37.77
Net change in Cash -0.08
Free Cash Flow 196.80
Particulars MAR 2022 (Values in Cr)
Net Income 121.12
Cash from Operations 52.75
Cash from Investing -103.86
Cash from Financing 80.47
Net change in Cash 0.21
Free Cash Flow 156.73
Particulars MAR 2021 (Values in Cr)
Net Income 89.07
Cash from Operations 14.84
Cash from Investing -73.10
Cash from Financing 81.33
Net change in Cash 0.06
Free Cash Flow 117.37
Particulars MAR 2025 (Values in Cr)
Net Income -141.11
Cash from Operations -13.42
Cash from Investing -15.13
Cash from Financing 23.62
Net change in Cash 0.10
Free Cash Flow 8.40
Particulars MAR 2024 (Values in Cr)
Net Income -61.87
Cash from Operations 12.05
Cash from Investing -134.97
Cash from Financing 124.85
Net change in Cash 0.00
Free Cash Flow 147.55
Particulars MAR 2023 (Values in Cr)
Net Income 34.84
Cash from Operations 79.18
Cash from Investing -112.07
Cash from Financing 37.66
Net change in Cash -0.08
Free Cash Flow 196.44
Particulars MAR 2022 (Values in Cr)
Net Income 121.04
Cash from Operations 52.53
Cash from Investing -103.56
Cash from Financing 80.36
Net change in Cash 0.21
Free Cash Flow 156.51
Particulars MAR 2021 (Values in Cr)
Net Income 88.67
Cash from Operations 14.92
Cash from Investing -73.10
Cash from Financing 81.22
Net change in Cash 0.05
Free Cash Flow 117.45
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
EXCEL INDUSTRIES LTD. 998.75 16.57 0.69 1255.50 801.00 1438.00
PUNJAB CHEMICALS AND CROP PROT 1002.80 18.76 2.90 1229.43 875.90 1664.95
DHANUKA AGRITECH LTD 1171.15 18.09 3.76 5279.35 889.95 1960.00
UPL LIMITED 632.55 28.31 1.53 53381.21 565.25 812.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
BAYER CROPSCIENCE LTD. 4386.35 29.41 6.31 19713.17 4276.85 6539.95
EXCEL INDUSTRIES LTD. 998.75 17.42 1.01 1255.50 801.00 1438.00
PUNJAB CHEMICALS AND CROP PROT 1002.80 19.52 2.77 1229.43 875.90 1664.95
RALLIS INDIA LTD 253.10 24.38 2.40 4922.01 216.10 385.60

ASTEC LIFESCIENCES LTD shareholding pattern

Holding
24.67%
71.96%
0.02%
3.33%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

ASTEC LIFESCIENCES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
771.80 4.77 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 743.70
  • 26 Days 700.50
  • 10 Days 727.30
  • 50 Days 677.60
  • 12 Days 723.10
  • 100 Days 672.10
  • 20 Days 709.40
  • 200 Days 712.30
742.20 PIVOT
First Support 725.45 First Resistance 753.40 Second Support 714.25 Second Resistance 770.15 Third Support 697.50 Third Resistance 781.35
RSI 62.09 ADX 24.56 MACD 22.56 Williams % R -16.91 Commodity Channel Index (CCI) 138.27
Date 2026-05-22 Week 39770.00 Same Day 37877.00 Month 28122.00
1 Year 1.13 3 Year 0.76
Over 1 Month
4.21% down
Over 1 Year
10.62% down
Over 3 Months
23.40% down
Over 3 Years
-18.46% down
Over 6 Months
-13.28% down
Over 5 Years
-11.99% down

ASTEC LIFESCIENCES LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
21 Jul 2023 1.5 Final 22 Jul 2023 Equity shares
19 Jul 2022 1.5 Final 21 Jul 2022 Equity shares
22 Jul 2021 1.5 Final 24 Jul 2021 Equity shares
16 Jul 2020 1.5 Final 18 Jul 2020 Equity shares
18 Jul 2019 1.5 Final 22 Jul 2019 Equity shares
19 Jul 2018 1.5 Final 23 Jul 2018 Equity shares
17 Jul 2017 1.5 Final 19 Jul 2017 Equity shares
15 Sep 2015 1.25 Final 18 Sep 2015 Equity shares
15 Sep 2014 1.0 Final 17 Sep 2014 Equity shares
02 Sep 2013 0.75 Final 04 Sep 2013 Equity shares
13 Sep 2012 0.5 Final 17 Sep 2012 Equity shares
15 Sep 2011 0.5 Final 19 Sep 2011 Equity shares
12 Aug 2010 1.0 Final 16 Aug 2010 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
21 Jul 2023 1.5 Final 22 Jul 2023 Equity shares
19 Jul 2022 1.5 Final 21 Jul 2022 Equity shares
22 Jul 2021 1.5 Final 24 Jul 2021 Equity shares
16 Jul 2020 1.5 Final 18 Jul 2020 Equity shares
18 Jul 2019 1.5 Final 22 Jul 2019 Equity shares
19 Jul 2018 1.5 Final 23 Jul 2018 Equity shares
17 Jul 2017 1.5 Final 19 Jul 2017 Equity shares
15 Sep 2015 1.25 Final 18 Sep 2015 Equity shares
15 Sep 2014 1.0 Final 17 Sep 2014 Equity shares
02 Sep 2013 0.75 Final 04 Sep 2013 Equity shares
13 Sep 2012 0.5 Final 17 Sep 2012 Equity shares
15 Sep 2011 0.5 Final 19 Sep 2011 Equity shares
12 Aug 2010 1.0 Final 16 Aug 2010 Equity shares

Top Gainers

Top Losers

ASTEC LIFESCIENCES LTD Share Price

Astec LifeSciences Limited was initially incorporated on January 25, 1994 as a private limited Company as 'Urshila Traders Private Limited'. The Company was originally promoted by Reena Bagai and Avita Fernandes. Their shareholding was purchased by Ashok Hiremath and Pratap Garud on February 11, 1994. On August 19, 1994, the name of the Company was changed from Urshila Traders Private Limited to Astec Chemicals Private Limited. In March 2006, the name was changed from Astec Chemicals Private Limited to Astec LifeSciences Private Limited. In April 2006, the company was converted into public limited Company and the name was changed to Astec LifeSciences Limited.

Astec LifeSciences is a producer of agrochemicals and pharmaceutical intermediates. The Company manufactures a wide range of Agrochemical active ingredients and pharmaceutical intermediates. They are having manufacturing facilities located at two locations in Maharashtra, India comprising of three units viz. one unit at Dombivli, Maharashtra and two units at Mahad, Maharashtra (Unit 1 and Unit 2). They are exporting their products to East Asia, Europe, Middle East, and USA. Godrej Agrovet Limited, the Holding Company has maintained its shareholding of 64.75% equity stake in the Company as on 31st March, 2025.

The business of the company comprises of the two major segments, namely Agrochemicals and Pharmaceuticals. Under the Agrochemical segment, the company manufactures active ingredients, intermediates and formulations. Active ingredients are sold to crop protection formulators. Intermediates are supplied to technical grade product manufacturers. Formulations are sold in bulk quantities to companies engaged in retail marketing. Under the Pharmaceutical segment, the company carries out manufacturing of intermediates which are supplied to Active Pharma Ingredients (API) manufacturers.

In August 1994, the company started their first manufacturing unit by acquiring a sick unit in Dombivli, Maharashtra having an installed capacity of 120 MT for the manufacture of Dicap, a pharmaceutical intermediate. In May 2001, they were awarded ISO 9002 Certification by International Standards Certification Pty Limited, Australia.

In February 18, 2002, the company entered into an agreement with Behram Chemicals Pvt Ltd with a view to expand their operations for using and operating their manufacturing facilities located at Mahad in Maharashtra. Behram Chemicals Pvt Ltd was engaged in manufacture of chemicals and pesticides with installed capacity of 130 MT.

During the year 2003-04, the company expanded the total installed capacity of their units (Dombivli and Mahad) from 250 MT to 500 MT. In the year 2004, they acquired a plot of land located at Mahad, Maharashtra. In May 2005, they set up a new manufacturing facility as an Export Oriented Unit (as Unit 2), which is adjacent to Unit 1 with an installed capacity of 1000 MT. With the commissioning of Unit 2, the company's total installed capacity increased to 1500 MT.

During the year 2006-07, the company further expanded their total capacities to 2000 MT. In January 2007, they established Astec Europe in Tournai, Belgium.

During the year 2007-08, the company increased the production capacity of Agro & Pharma Intermediates by 500 MT to 2500 MT In April 2007, Behram Chemicals Pvt Ltd became the subsidiary of the company by the acquisition of 65.63% equity by the company vide Share Purchase Agreement.

During the year 2008-09, the company increased the production capacity of Agro & Pharma Intermediates by 300 MT to 2800 MT. They established a relationship with a major multinational for supply of one of our products into the global supply chain.

During the year 2009-10, the company increased the production capacity of Agro & Pharma Intermediates by 350 MT to 3150 MT. They also introduced new measures to improve EHS performance. In December 2009, the company has bagged orders worth Rs 7 crore from Syngenta India and Nufarm, which are amongst the world's top ten largest agrochemical manufacturing companies.

In June 2010, the company entered into a long term mutually exclusive confidential contract to supply an herbicide to a multinational agrochemical major. In August 2010, the company acquired land in MIDC Mahad area admeasuring 40000 sq mtrs with a view to set up additional manufacturing facilities on the new site.

In August 27, 2010, the company's Chairman & Managing Director, Ashok V Hiremath was awarded Prestigious 'Business Excellence' Award by the 'Indo-Thai Entrepreneurs Summit' Bangkok, Thailand for his outstanding contribution towards progress and development of Indian Economy and Society.

The Company incorporated a 100% wholly owned subsidiary, Astec CropCare Pvt. Ltd. to start the business of trading in agrochemicals and pesticides formulations to sell products. It made investments to increase the capacity of its manufacturing facility and to improvc the quality of products in Mahad. Work was started on construction of new 40000 sq m site at Mahad in Apr' 11.

During the year 2012-13, the Company has set-up a new subsidiary namely, Comercializadora Agricola Agroastrachem Cia Ltda in Bagota, Columbia.

During period 2015-16, the Company became a majority-owned subsidiary of Godrej Agrovet Limited with effect from 6th November, 2015.

During Financial Year 2020-21, Company sold off its entire equity stake in Astec Europe Sprl (a 50.10% subsidiary of Company in Belgium, Europe), in terms of a Share Purchase Agreement executed on 31st August 2020. Accordingly, Astec Europe Sprl ceased to be a subsidiary of Company with effect from 1st September, 2020.

During the Financial Year 2021-22, Company also commissioned its new herbicide plant and completed first batch of CMO product. It commercialized two new CMO products and a new production process for an enterprise product.

In April 2023, Company inaugurated a state-of-the-art Research & Development (R&D) Centre, named 'Adi Godrej Centre for Chemical Research and Development' in Rabale, Maharashtra. The Company commissioned a herbicide plant in FY 2024-25 to cater to Contract Manufacturing business.

Parent organization Godrej
NSE symbol ASTEC
Founded 1994
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Astec Lifesciences Ltd?

Answer Field

Astec Lifesciences Ltd share price is for NSE ₹ 771.80 & for BSE ₹ 768.00 as on May 22 2026 03:30 PM.

What is the Market Cap of Astec Lifesciences Ltd Share?

Answer Field

The market cap of Astec Lifesciences Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on May 22 2026 03:30 PM.

What is the 52 Week High and Low of Astec Lifesciences Ltd?

Answer Field

The 52 Week High and Low of Astec Lifesciences Ltd for NSE is ₹ 990.82 and ₹ 513.40 and for BSE is ₹ 990.87 and ₹ 512.35.

What is 1 year return for Astec Lifesciences Ltd?

Answer Field

The 1 year returns on the stock has been 10.62%.

What is the P/E Ratio of Astec Lifesciences Ltd Share?

Answer Field

As on May 22 2026 03:30 PM the price-to-earnings (PE) ratio for Astec Lifesciences Ltd share is -21.25.

What is the PB ratio of Astec Lifesciences Ltd Share?

Answer Field

As on May 22 2026 03:30 PM, the price-to-book (PB) ratio for Astec Lifesciences Ltd share is 174.96.

How to Buy Astec Lifesciences Ltd Share?

Answer Field

You can trade in Astec Lifesciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Astec Lifesciences Ltd Share on Bajaj Broking App?

Answer Field

To buy Astec Lifesciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Astec Lifesciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|